Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
7
×
boston blog main
deals
7
×
life sciences
national blog main
national top stories
7
×
san francisco blog main
7
×
boston top stories
san francisco top stories
clinical trials
startups
boston
ipo
new york blog main
new york top stories
alnylam pharmaceuticals
cancer
eli lilly
fda
genentech
hepatitis b
indiana blog main
indiana top stories
investing
raleigh-durham blog main
raleigh-durham top stories
roche
san diego blog main
san diego top stories
san francisco
sanofi
sickle cell disease
third rock ventures
vc
venture capital
vir biotechnology
warp drive bio
wisconsin blog main
wisconsin top stories
abbvie
What
medicines
7
×
deal
drug
new
biotech
cancer
ipo
research
startup
abandoning
acquisitions
adds
ago
aiming
aims
alliance
ambys
announced
approach
approval
areas
baggage
based
big
bio
biosciences
bio’s
blueprint
brii
called
candidate
ceo
collabs
companies
control
covid
currently
cuts
daniel
deadly
Language
unset
Current search:
deals
×
medicines
×
" san francisco blog main "
×
biotech
×
" national top stories "
×
@xconomy.com
3 years ago
Roche, Blueprint Medicines Team Up Again in $775M RET Cancer Drug Pact
@xconomy.com
4 years ago
Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More
@xconomy.com
4 years ago
Revolution Medicines IPO Reels In $238M to Take On RAS in Cancer
@xconomy.com
4 years ago
Flagship’s Omega Aims to Take Epigenetic Drugs a Step Further
@xconomy.com
5 years ago
Brii Bio’s Alliance with VBI Vaccines Adds Hepatitis B Drug to Pipeline
@xconomy.com
5 years ago
Free of Baggage, Dicerna Cuts Another RNAi Deal and Gets $200M
@xconomy.com
5 years ago
With Big Takeda Deal at Launch, Can Ambys Keep Control of Its Future?